HMGA2 and gastric cancer: Therefore, the CRISPR/Cas9-3NLS/sgHMGA2@PDA delivery system can achieve desired CRISPR/Cas9-3NLS/sgHMGA2 delivery efficiency and HMGA2 gene editing ability in vitro and in vivo to treat GC with high expression of HMGA2.